Heinrich, N.* et al. Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): A prospective, open-label, randomised, phase 2b dose-finding trial. Lancet Infect. Dis., DOI: 10.1016/S1473-3099(25)00213-0 (2025)
Minja, L.T.* et al. Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): A prospective, randomised, open-label, phase 2b, dose-finding trial. Lancet Infect. Dis., DOI: 10.1016/S1473-3099(25)00289-0 (2025)
Kocher, K.* et al. Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual. Lancet Infect. Dis. 24, e272-e274 (2024)
Olbrich, L.* et al. Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: A secondary analysis of the RaPaed-TB study. Lancet Infect. Dis. 25, 188-197 (2024)
Olbrich, L.* et al. Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries. Lancet Infect. Dis. 24, 140-149 (2023)
Tenbusch, M.* et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect. Dis. 21, 1212-1213 (2021)